BioSpace News Archive

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, confirmed that it will report second quarter 2020 financial results on Wednesday, August 5, 2020 after the market closes.

CareDx, Inc. announces that Peter Maag, Chairman and CEO of CareDx, will present at a panel hosted by the American Association of Kidney Patients and the George Washington University School of Medicine and Health Sciences on “Emerging Innovation in Kidney Disease with Global Implications: Artificial Intelligence in Transplant Care.” The summit is scheduled to be held from July 16 to July 17, 2020.

Hillrom announced that its board of directors declared a fiscal 2020 fourth quarter dividend of $0.22 per share payable on September 30, 2020, to shareholders of record as of the close of business on September 18, 2020.

RxE2 announced the appointment of Tina Schlecht, Pharm. D. as the company’s Vice President of Pharmacy Operations.

Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office.

Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization, announces the addition of Mass Spectrometry to its Analytical Development suite of services.

Terumo Corporation announced it has completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radiation Therapy, a treatment for liver tumors.

Stress of Balancing Personal, Professional Demands Outstrips Concerns with Compensation, Parity

Orchard Therapeutics, a global gene therapy leader, announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc for use of their proprietary lentiviral stable cell line technology for Orchard’s investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia.